Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Releases 68th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube May 15, 2023

The National Medical Products Administration (NMPA) has released the 68th batch of reference drugs for...

Company Medical Device

Basecare Medical to Acquire BMX Holdco for $40 Million, Expanding IVF Portfolio

Fineline Cube May 15, 2023

China-based in vitro fertilization (IVF) specialist, Suzhou Basecare Medical Co., Ltd (HKG: 2170), has announced...

Company Deals

Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology

Fineline Cube May 12, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Deals

First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials

Fineline Cube May 12, 2023

First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of...

Policy / Regulatory

China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices

Fineline Cube May 12, 2023

The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...

Company

Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact

Fineline Cube May 12, 2023

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,...

Company Drug

Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE

Fineline Cube May 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia

Fineline Cube May 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled...

Company Deals Digital

ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development

Fineline Cube May 12, 2023

ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic...

Drug Legal / IP

CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China

Fineline Cube May 11, 2023

The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...

Company Drug

Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...

Company Drug

Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its...

Company Drug

CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo

Fineline Cube May 11, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for...

Company Drug

Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults

Fineline Cube May 11, 2023

China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing...

Policy / Regulatory

Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion

Fineline Cube May 11, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification outlining key tasks for the...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer

Fineline Cube May 11, 2023

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that...

Company Drug

Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC

Fineline Cube May 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB)...

Company Drug

Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA

Fineline Cube May 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has announced that the...

Company Deals

Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China

Fineline Cube May 10, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

Mabwell Bioscience’s 9MW3911 Receives NMPA Approval for Clinical Trial in Advanced Tumors

Fineline Cube May 10, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Posts pagination

1 … 518 519 520 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.